Further to studies demonstrating the role of LVEF in assessing and/or predicting CTRCD [118,146], Stoodley et al., 2013 [147], revealed a significant reduction in global systolic strain (GSS) (myocardial imaging) in HER2-negative breast cancer patients promptly after (−19.0 ± 2.3% to −17.5 ± 2.3%; p < 0.001) and at 6 months of anthracycline therapy −8.2 ± 2.2%; p = 0.01). This evidence concerns the gene ERBB2 and breast carcinoma.